An observational study in Colorectal Cancer, sponsored by N-Power Medicine. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by N-Power Medicine · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The goal of this observational, external control arm study is to make clinical trials faster, speed up developments of new therapies, and make trials more accessible to patients being treated at community oncology clinics.
The purpose of this research is to better understand what treatments are given to patients with colorectal cancer, how the disease responds to treatments, and the generate reliable data that can be used as a comparison for new drugs in development.
6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
This study's planned enrollment of 650 is above the median of 250 across 1,442 observational studies indexed under Colorectal Neoplasms.
Browse Colorectal Neoplasms studies →N-Power Medicine is the lead sponsor of 4 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with early stage or metastatic colorectal cancer
Global Inclusion Criteria:
Early Stage CRC Inclusion Criteria
CRC Inclusion Criteria
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Progression Free Survival (PFS)
Time from index date to the first evidence of progression assessed by Blinded Independent Central Review (BICR) per RECIST 1.1 for on protocol imaging, or death, whichever occurs first. bicrPFS (months)=\[(earliest date of BICR progression, death, or censoring-index date) +1\] / 30.4375
Time frame: 5 years
Overall Response Rate (ORR)
Proportion of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) during a given line of therapy, from index until progression or the start of the next line, whichever occurs first, assessed by Blinded Independent Central Review (BICR) per RECIST 1.1 for on-protocol imaging. Ranked CR ≥ PR ≥ stable disease (SD) ≥ progressive disease (PD) ≥ not evaluable (NE). CR and PR are confirmed by a subsequent assessment at least 28 days later. When the minimum interval is not met, BOR is determined by subsequent assessments. Participants lost to follow-up after an SD assessment that does not meet the minimum interval have a BOR of NE. bicrORR (%) = (number of participants with BOR of CR or PR from index until earliest date of BICR progression or next line start ÷ number of participants in the response population) × 100
Time frame: 5 years
Time to Next Treatment (TTNT)
Time from index to the start of the next line of therapy or death, whichever occurs first. Participants who do not initiate a next line of therapy are censored at earliest of loss to followup and data cutoff. TTNT (months) = \[(earliest date of next line start, death, or censoring - index date) + 1\] ÷ 30.4375.
Time frame: 5 years
Overall Survival (OS)
Time from index to death from any cause. A missing date of death indicates the participant is alive at data cutoff, and the participant is censored at data cutoff. OS (months) = \[(earliest date of death or censoring - index date) + 1\] ÷ 30.4375
Time frame: 5 years
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2031, 60 months later.
Of 117 industry-sponsored observational studies under Colorectal Neoplasms, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 60. This study's planned 60 months is above that.
Counting every sponsor, half of 647 studies reached it within 52 months; a quarter within 27 and three quarters within 104.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
N-Power Medicine